Recent reports demonstrate that recurrent mutations in NFKB2 are drivers for CLL progression [13,14], and in the case of MCL, resistance to ibrutinib is defined by aberrant non-canonical NF-κB signalling due to mutations in TRAF2 or BIRC3 [11]. The gene discussed is NFKB1; the disease is mantle cell lymphoma.